Publication Name	World Journal of Clinical Oncology
Manuscript ID	19752
Country	Italy

Received	2015-05-20 09:02
Peer-Review Started	2015-05-20 21:49
To Make the First Decision	2015-07-02 13:30
Return for Revision	2015-07-10 14:35
Revised	2015-07-16 21:02
Second Decision	2015-08-13 10:16
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-08-21 16:17
Articles in Press	2015-08-21 16:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-28 14:52
Publish the Manuscript Online	2015-10-13 10:26

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Current and future treatment of anaplastic lymphoma kinase-rearranged cancer
Manuscript Source	Invited Manuscript
All Author List	Luca Mologni
Funding Agency and Grant Number	Funding Agency Grant Number Italian Association for Cancer Research AIRC 2013 IG-14249
Corresponding Author	Luca Mologni, PhD, Molecular Oncology Lab, Department Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy. luca.mologni@unimib.it
Key Words	Anaplastic lymphoma kinase tyrosine kinase receptor; Protein kinase inhibitors; Drug resistance; Crizotinib; Drug combinations
Core Tip	In this Editorial article, I discuss the issue of anaplastic lymphoma kinase (ALK) driven cancer and its specific treatment with selective ALK tyrosine kinase inhibitors. The problem of acquired drug resistance is shortly reviewed and clinical data with novel investigational ALK inhibitors are presented. The possibility of specific combination therapies is briefly discussed.
Publish Date	2015-10-13 10:26
Citation	Mologni L. Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World J Clin Oncol 2015; 6(5): 104-108
URL	http://www.wjgnet.com/2218-4333/full/v6/i5/104.htm
DOI	http://dx.doi.org/10.5306/wjco.v6.i5.104

Full Article (PDF)	WJCO-6-104.pdf
Full Article (Word)	WJCO-6-104.doc
Manuscript File	19752-Review.docx
Answering Reviewers	19752-Answering reviewers.pdf
Audio Core Tip	19752-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19752-Conflict-of-interest statement.pdf
Copyright License Agreement	19752-Copyright assignment.pdf
Peer-review Report	19752-Peer-review(s).pdf
Scientific Misconduct Check	19752-Scientific misconduct check.pdf
Scientific Editor Work List	19752-Scientific editor work list.pdf